JGC
SEEL

J. Goldman & Co’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

J. Goldman & Co’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14
Closed -$130K – 471
2021
Q3 		$130K Sell
14
-476
-97% -$4.09M 0.01% 316
2021
Q2 		$4.97M Buy
490
+478
+3,983% +$7.85M 0.19% 137
2021
Q1 		$236K Buy
+12
New +$140K 0.01% 392

Other funds holding SEEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

J. Goldman & Co's SEEL Position: Q4 2021 in Review

J. Goldman & Co sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2021, closing a stake of 14 shares — an estimated $130K sold.

J. Goldman & Co first reported a position in SEEL in Q1 2021 and held it in 3 quarters. The position peaked at $4.97M in Q2 2021. 82 funds tracked by Wall St. Rank hold SEEL as of Q4 2021.

  • J. Goldman & Co reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • J. Goldman & Co sold 14 Seelos Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $130K.
  • J. Goldman & Co first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • J. Goldman & Co's Seelos Therapeutics, Inc. Common Stock position peaked at $4.97M in Q2 2021.
  • 82 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2021.

Based on J. Goldman & Co's 13F filing for Q4 2021, filed 14 Feb 2022.